Email Sign-Up
 
63 results found
Filter Filters icon
Apply

Article

Ribociclib

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Article

Palbociclib

Palbociclib (Ibrance), a targeted therapy, was the first CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Article

Abemaciclib

Abemaciclib (Verzenio) is a targeted therapy approved by the Food and Drug Administration to treat hormone receptor-positive breast cancer.

Article

Targeted therapy for hormone receptor-positive breast cancer

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy. Hormonal ...

Article

Trastuzumab deruxtecan

Trastuzumab deruxtecan (Enhertu) is an antibody drug conjugate approved to treat people with metastatic, HER2-positive, hormone receptor-negative breast cancer that has grown after at least two ...

Story 12/19/22

Ibrance adds no benefit over Faslodex alone

Participants with HR-positive metastatic breast cancer saw no benefit from adding the CDK inhibitor but a small group who also got immunotherapy had a longer period without disease growth

Story 12/13/22

New breast cancer drug targets AKT pathway

Capivasertib on track for possible FDA approval in metastatic hormone receptor-positive disease

Story 12/09/22

Elacestrant on course to gain FDA approval

Elacestrant is poised to move forward as a new option for metastatic hormone receptor-positive, HER2-negative  breast cancer in 2023. New results point to a relationship between the drug’s ...

Story 06/05/23

Enhertu continues to show good results

Two studies support use of trastuzumab deruxtecan for metastatic HER2-positive breast cancer 

Story 12/07/22

Abemaciclib, everolimus studied in high-risk, early-stage HR-positive breast cancer

New findings from two studies presented at SABCS confirm abemaciclib plus endocrine therapy reduces risk of recurrence, while adding everolimus does not improve outcomes